INCYTE CORPORATION Net Income (Loss) Available to Common Stockholders, Diluted
INCYTE CORPORATION (INCY) reported Net Income (Loss) Available to Common Stockholders, Diluted of $303.33 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-28.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-04-28
- INCYTE CORPORATION net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was $303.33M, a 91.73% increase year-over-year.
- INCYTE CORPORATION net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was $299.28M, a 48.74% increase year-over-year.
- INCYTE CORPORATION net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was $424.17M, a 298.45% increase year-over-year.
- INCYTE CORPORATION net income (loss) available to common stockholders, diluted for the quarter ending 2025-06-30 was $405.00M.
- INCYTE CORPORATION net income (loss) available to common stockholders, diluted for fiscal 2025 was $1.29B, a 3844.96% increase from fiscal 2024.
- INCYTE CORPORATION net income (loss) available to common stockholders, diluted for fiscal 2024 was $32.62M, a 94.54% decline from fiscal 2023.
- INCYTE CORPORATION net income (loss) available to common stockholders, diluted for fiscal 2023 was $597.60M, a 75.42% increase from fiscal 2022.
- INCYTE CORPORATION net income (loss) available to common stockholders, diluted for fiscal 2022 was $340.66M, a 64.09% decline from fiscal 2021.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-03-31 | $303.33M 10-Q · filed 2026-04-28 | $602.61M derived: sum of 2 quarters · filed 2026-04-28 | $1.03B derived: sum of 3 quarters · filed 2026-04-28 | $1.43B derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-12-31 | $299.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $723.45M derived: sum of 2 quarters · filed 2026-02-10 | $1.13B derived: sum of 3 quarters · filed 2026-02-10 | $1.29B 10-K · filed 2026-02-10 |
| 2025-09-30 | $424.17M 10-Q · filed 2025-10-28 | $829.17M derived: sum of 2 quarters · filed 2025-10-28 | $987.37M 10-Q · filed 2025-10-28 | $1.19B derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-06-30 | $405.00M 10-Q · filed 2025-07-29 | $563.20M 10-Q · filed 2025-07-29 | $764.41M derived: sum of 3 quarters · filed 2026-04-28 | $870.87M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-03-31 | $158.20M 10-Q · filed 2026-04-28 | $359.42M derived: sum of 2 quarters · filed 2026-04-28 | $465.87M derived: sum of 3 quarters · filed 2026-04-28 | $21.27M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $201.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $307.67M derived: sum of 2 quarters · filed 2026-02-10 | -$136.93M derived: sum of 3 quarters · filed 2026-02-10 | $32.62M 10-K · filed 2026-02-10 |
| 2024-09-30 | $106.46M 10-Q · filed 2025-10-28 | -$338.14M derived: sum of 2 quarters · filed 2025-10-28 | -$168.60M 10-Q · filed 2025-10-28 | $32.48M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-30 | -$444.60M 10-Q · filed 2025-07-29 | -$275.05M 10-Q · filed 2025-07-29 | -$73.97M derived: sum of 3 quarters · filed 2026-02-10 | $97.30M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-31 | $169.55M 10-Q · filed 2025-04-29 | $370.63M derived: sum of 2 quarters · filed 2026-02-10 | $541.90M derived: sum of 3 quarters · filed 2026-02-10 | $745.44M derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-31 | $201.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $372.35M derived: sum of 2 quarters · filed 2026-02-10 | $575.90M derived: sum of 3 quarters · filed 2026-02-10 | $597.60M 10-K · filed 2026-02-10 |
| 2023-09-30 | $171.27M 10-Q · filed 2024-10-29 | $374.82M derived: sum of 2 quarters · filed 2024-10-29 | $396.52M 10-Q · filed 2024-10-29 | $424.98M derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-06-30 | $203.55M 10-Q · filed 2024-07-30 | $225.25M 10-Q · filed 2024-07-30 | $253.71M derived: sum of 3 quarters · filed 2025-02-10 | $366.49M derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-03-31 | $21.70M 10-Q · filed 2024-04-30 | $50.16M derived: sum of 2 quarters · filed 2025-02-10 | $162.94M derived: sum of 3 quarters · filed 2025-02-10 | $324.37M derived: sum of 4 quarters · filed 2025-02-10 |
| 2022-12-31 | $28.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $141.24M derived: sum of 2 quarters · filed 2025-02-10 | $302.67M derived: sum of 3 quarters · filed 2025-02-10 | $340.66M 10-K · filed 2025-02-10 |
| 2022-09-30 | $112.78M 10-Q · filed 2023-10-31 | $274.21M derived: sum of 2 quarters · filed 2023-10-31 | $312.20M 10-Q · filed 2023-10-31 | $876.05M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $161.43M 10-Q · filed 2023-08-01 | $199.42M 10-Q · filed 2023-08-01 | $763.27M derived: sum of 3 quarters · filed 2024-02-13 | $945.01M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | $37.99M 10-Q · filed 2023-05-02 | $601.84M derived: sum of 2 quarters · filed 2024-02-13 | $783.58M derived: sum of 3 quarters · filed 2024-02-13 | $933.04M derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $563.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $745.59M derived: sum of 2 quarters · filed 2024-02-13 | $895.05M derived: sum of 3 quarters · filed 2024-02-13 | $948.58M 10-K · filed 2024-02-13 |
| 2021-09-30 | $181.74M 10-Q · filed 2022-11-01 | $331.19M derived: sum of 2 quarters · filed 2022-11-01 | $384.73M 10-Q · filed 2022-11-01 | $534.58M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-06-30 | $149.46M 10-Q · filed 2022-08-02 | $202.99M 10-Q · filed 2022-08-02 | $352.84M derived: sum of 3 quarters · filed 2023-02-07 | $337.64M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-03-31 | $53.53M 10-Q · filed 2022-05-03 | $203.38M derived: sum of 2 quarters · filed 2023-02-07 | $188.18M derived: sum of 3 quarters · filed 2023-02-07 | $478.48M derived: sum of 4 quarters · filed 2023-02-07 |
| 2020-12-31 | $149.85M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $134.65M derived: sum of 2 quarters · filed 2023-02-07 | $424.94M derived: sum of 3 quarters · filed 2023-02-07 | -$295.70M 10-K · filed 2023-02-07 |
| 2020-09-30 | -$15.20M 10-Q · filed 2021-11-02 | $275.10M derived: sum of 2 quarters · filed 2021-11-02 | -$445.55M 10-Q · filed 2021-11-02 | -$334.54M derived: sum of 4 quarters · filed 2022-02-08 |
| 2020-06-30 | $290.30M 10-Q · filed 2021-08-03 | -$430.34M 10-Q · filed 2021-08-03 | -$319.34M derived: sum of 3 quarters · filed 2022-02-08 | -$191.07M derived: sum of 4 quarters · filed 2022-02-08 |
| 2020-03-31 | -$720.64M 10-Q · filed 2021-05-04 | -$609.64M derived: sum of 2 quarters · filed 2022-02-08 | -$481.37M derived: sum of 3 quarters · filed 2022-02-08 | -$376.05M derived: sum of 4 quarters · filed 2022-02-08 |
| 2019-12-31 | $111.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-08 | $239.28M derived: sum of 2 quarters · filed 2022-02-08 | $344.59M derived: sum of 3 quarters · filed 2022-02-08 | $446.91M 10-K · filed 2022-02-08 |
| 2019-09-30 | $128.27M 10-Q · filed 2020-11-05 | $233.59M derived: sum of 2 quarters · filed 2020-11-05 | $335.90M 10-Q · filed 2020-11-05 | $404.96M derived: sum of 4 quarters · filed 2021-02-09 |
| 2019-06-30 | $105.32M 10-Q · filed 2020-08-04 | $207.63M 10-Q · filed 2020-08-04 | $276.69M derived: sum of 3 quarters · filed 2021-02-09 | $305.87M derived: sum of 4 quarters · filed 2021-02-09 |
| 2019-03-31 | $102.31M 10-Q · filed 2020-05-05 | $171.38M derived: sum of 2 quarters · filed 2021-02-09 | $200.55M derived: sum of 3 quarters · filed 2021-02-09 | $252.94M derived: sum of 4 quarters · filed 2021-02-09 |
| 2018-12-31 | $69.06M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-09 | $98.24M derived: sum of 2 quarters · filed 2021-02-09 | $150.63M derived: sum of 3 quarters · filed 2021-02-09 | $109.49M 10-K · filed 2021-02-09 |
| 2018-09-30 | $29.18M 10-Q · filed 2019-10-29 | $81.57M derived: sum of 2 quarters · filed 2019-10-29 | $40.43M 10-Q · filed 2019-10-29 | -$109.20M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-06-30 | $52.39M 10-Q · filed 2019-07-30 | $11.25M 10-Q · filed 2019-07-30 | -$138.38M derived: sum of 3 quarters · filed 2020-02-13 | -$102.32M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-03-31 | -$41.14M 10-Q · filed 2019-04-30 | -$190.77M derived: sum of 2 quarters · filed 2020-02-13 | -$154.72M derived: sum of 3 quarters · filed 2020-02-13 | -$167.20M derived: sum of 4 quarters · filed 2020-02-13 |
| 2017-12-31 | -$149.63M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | -$113.58M derived: sum of 2 quarters · filed 2020-02-13 | -$126.06M derived: sum of 3 quarters · filed 2020-02-13 | -$313.14M 10-K · filed 2020-02-13 |
| 2017-09-30 | $36.05M 10-Q · filed 2018-10-30 | $23.57M derived: sum of 2 quarters · filed 2018-10-30 | -$163.51M 10-Q · filed 2018-10-30 | -$154.64M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-06-30 | -$12.48M 10-Q · filed 2018-07-31 | -$199.57M 10-Q · filed 2018-07-31 | -$190.69M derived: sum of 3 quarters · filed 2019-02-14 | -$153.82M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-03-31 | -$187.08M 10-Q · filed 2017-05-04 | -$178.21M derived: sum of 2 quarters · filed 2019-02-14 | -$141.33M derived: sum of 3 quarters · filed 2019-02-14 | -$106.91M derived: sum of 4 quarters · filed 2019-02-14 |
| 2016-12-31 | $8.87M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | $45.75M derived: sum of 2 quarters · filed 2019-02-14 | $80.17M derived: sum of 3 quarters · filed 2019-02-14 | $104.22M 10-K · filed 2019-02-14 |
| 2016-09-30 | $36.88M 10-Q · filed 2017-10-31 | $71.30M derived: sum of 2 quarters · filed 2017-10-31 | $95.35M 10-Q · filed 2017-10-31 | $150.53M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | $34.42M 10-Q · filed 2017-08-01 | $58.47M 10-Q · filed 2017-08-01 | $113.65M derived: sum of 3 quarters · filed 2018-02-15 | $74.07M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | $24.05M 10-Q · filed 2017-05-04 | $79.22M derived: sum of 2 quarters · filed 2018-02-15 | $39.64M derived: sum of 3 quarters · filed 2018-02-15 | $48.94M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $55.18M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $15.59M derived: sum of 2 quarters · filed 2018-02-15 | $24.89M derived: sum of 3 quarters · filed 2018-02-15 | $6.53M 10-K · filed 2018-02-15 |
| 2015-09-30 | -$39.58M 10-Q · filed 2016-11-01 | -$30.29M derived: sum of 2 quarters · filed 2016-11-01 | -$48.65M 10-Q · filed 2016-11-01 | -$85.59M derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-06-30 | $9.29M 10-Q · filed 2016-08-09 | -$9.06M 10-Q · filed 2016-08-09 | -$46.01M derived: sum of 3 quarters · filed 2017-02-14 | $16.16M derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-03-31 | -$18.36M 10-Q · filed 2016-05-09 | -$55.30M derived: sum of 2 quarters · filed 2017-02-14 | $6.87M derived: sum of 3 quarters · filed 2017-02-14 | -$30.01M derived: sum of 4 quarters · filed 2017-02-14 |
| 2014-12-31 | -$36.94M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | $25.22M derived: sum of 2 quarters · filed 2017-02-14 | -$11.65M derived: sum of 3 quarters · filed 2017-02-14 | -$48.48M 10-K · filed 2017-02-14 |
| 2014-09-30 | $62.17M 10-Q · filed 2015-11-03 | $25.29M derived: sum of 2 quarters · filed 2015-11-03 | -$11.54M 10-Q · filed 2015-11-03 | |
| 2014-06-30 | -$36.87M 10-Q · filed 2015-08-04 | -$70.83M 10-Q · filed 2015-08-04 | ||
| 2013-12-31 | -$42.87M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | -$64.91M derived: sum of 2 quarters · filed 2016-02-12 | -$83.15M 10-K · filed 2016-02-12 | |
| 2013-09-30 | -$22.04M 10-Q · filed 2014-10-30 | -$40.28M 10-Q · filed 2014-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |